What Yuvezzi brings to the optometrist's clinical toolkit with Dr Derek Cunningham

As pharmacologic options for presbyopia evolve, new therapies are expanding how optometrists approach near-vision correction and patient counseling. In this Q&A, Derek N. Cunningham, OD, FAAO, discusses carbachol and brimonidine tartrate ophthalmic solution (Yuvezzi) 2.75%/0.1% in light of its recent FDA approval and explores how it may fit into everyday clinical practice. The conversation covers candidate selection, mechanism of action, patient education, and how drops can be integrated alongside traditional spectacle correction as part of a personalized presbyopia treatment strategy.